Screener / SEC EDGAR /CIK 0001727196 /10-K filed Mar 3, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Scholar Rock Holding Corp SRRK

Compare with peers Embed
Earnings releases

Latest results release: Nov 10, 2026

8-K item 2.02, exhibit 99

What SRRK's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 10, 2026 · EX-99.1

Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business

Open on SEC

Exhibit 99.1 Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights U.S. launch of ISEMBYLD™ (apitegromab-mstn), the first and only muscle-targeted therapy for children and adults living with spinal muscular atrophy (SMA), underway following September 11, 2026 FDA approval

ISEMBYLD shipped to specialty network prior to quarter-end, reflecting Q3 2026 ISEMBYLD revenue of $0.6 million

Strong early patient and physician demand for ISEMBYLD, with initial patients infused in October 2026

Apitegromab Marketing Authorisation Application (MAA) for treatment of children and adults living with SMA resubmitted to European Medicines Agency (EMA) and validated in October 2026; on track for Committee for Medicinal Products for Human Use (CHMP) opinion in H1 2027

Apitegromab Japanese New Drug Application (JNDA) for treatment of children and adults living with SMA submitted to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and accepted under priority review

Cash, cash equivalents, and marketable securities of $413.6 million as of September 30, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)— November 10, 2026 — Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today reported financial results for the third quarter ended September 30, 2026, and provided an update on recent company developments.

“The third quarter was a defining period for Scholar Rock, marked by the FDA approval and U.S. launch of ISEMBYLD, the world’s first and only muscle-targeted therapy for children and adults living with SMA,” said David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock. “We are very encouraged by the early ISEMBYLD launch dynamics in the U.S., where the breadth of early demand across SMA treatment centers, physicians, and patients reinforces the significant unmet need in the SMA community. With the U.S. launch underway, our regulatory applications advancing in Europe and Japan, important progress across our world-leading anti-myostatin pipeline, and our strengthened financial position, we are building a foundation to redefine the treatment of neuromuscular disease globally and drive sustainable growth for years to come.”

ISEMBYLD (apitegromab-mstn) approved by FDA on September 11, 2026. ISEMBYLD is the first and only muscle-targeted therapy for SMA and is indicated for adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted

treatment. In the Phase 3 pivotal, randomized, double-blind, placebo-controlled SAPPHIRE study, individuals receiving ISEMBYLD with an SMN2-targeted treatment demonstrated a robust, clinically meaningful improvement in motor function at one year while those on an SMN2-targeted therapy alone experienced a loss of motor function.

U.S. launch of ISEMBYLD underway with strong early patient and physician demand . The U.S. team is in the field engaging with physicians, SMA care teams, and patients as well as national and regional payers. ISEMBYLD vials were labeled, packaged, and shipped to the specialty network within one week of FDA approval. A J-code application was submitted to the Centers for Medicare & Medicaid Services (CMS) in September for an ISEMBYLD-specific J-code on April 1, 2027. Encouraging early, broad-based demand for ISEMBYLD is reflected in the breadth of prescribing physicians and enrolling patients. Early launch dynamics are reinforcing the significant opportunity to serve children and adults with SMA in the U.S.

Apitegromab application in Europe on track for H1 2027 Committee for Medicinal Products for Human Use (CHMP) opinion . In alignment with guidance from the European Medicines Agency (EMA), Scholar Rock resubmitted the apitegromab Marketing Authorisation Application (MAA) for the treatment of children and adults living with SMA in October 2026. Following validation of the submission, review of the MAA is underway, and the Company expects a CHMP opinion in the first half of 2027. The resubmitted MAA includes Scholar Rock’s alternate fill- finish facility in place of the Catalent Indiana LLC fill-finish facility. The alternate fill-finish facility is the same site that supported the U.S. FDA approval of ISEMBYLD in September 2026. As the regulatory review progresses, the Scholar Rock team in Europe continues to engage with key stakeholders on SMA disease awareness and education initiatives.

Apitegromab Japanese New Drug Application (JNDA) submitted in Japan and accepted under priority review. Scholar Rock submitted the apitegromab JNDA in Japan, which was accepted under priority review. For priority review applications, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has typically targeted a review cycle of approximately nine months. In addition, apitegromab for the treatment of people living with SMA was granted an Orphan Drug Designation.

Regulatory engagement for subcutaneous apitegromab program to progress. Scholar Rock has developed a high concentration subcutaneous formulation of apitegromab. Following the September 11, 2026 FDA approval of ISEMBYLD, the Company is engaging with regulators on the development path for this formulation. Subcutaneous apitegromab is designed to provide optionality for the SMA community as a small volume, self- or caregiver-administered anti-myostatin antibody.

Phase 2 OPAL trial advancing . Enrollment is well advanced and dosing is ongoing (NCT07047144). The OPAL study is evaluating apitegromab in infants and toddlers with SMA under two years of age who have received an approved SMN1-targeted gene therapy or who are receiving ongoing treatment with an approved SMN2-targeted therapy.

Enrollment and dosing in Phase 2 FORGE trial ongoing. The Phase 2 randomized, double-blind, placebo-controlled trial, called FORGE, is expected to enroll approximately 60 patients with FSHD who will be randomized 1:1 to receive either apitegromab 10mg/kg IV or placebo every 4 weeks for 52 weeks. The primary endpoint is mean lean muscle volume (LMV) change from baseline at 12 months. Other endpoints include safety, pharmacokinetics/ pharmacodynamics,

mean LMV change from baseline at 6 months, as well as several exploratory functional endpoints. In September 2026, the FDA granted Fast Track and Orphan Drug designations to apitegromab for the treatment of people living with FSHD.

Phase 1 study in healthy volunteers ongoing. A Phase 1 study evaluating SRK-439 in healthy volunteers is progressing well. Scholar Rock expects to have topline data by year end 2026 and plans to share data from this study in early 2027. SRK-439 is a novel, investigational, subcutaneously administered myostatin inhibitor that binds to pro- and latent myostatin with high affinity and selectivity. Based on non-clinical data, SRK-439 has the potential to potently inhibit myostatin and increase muscle mass.

Definitive agreement to sell Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. In November, Scholar Rock entered into a definitive agreement to sell its PRV for $205 million. The closing of the PRV transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. The cash will further strengthen the Company’s balance sheet with non-dilutive capital. The PRV was awarded following the September 2026 FDA approval of ISEMBYLD.

Scholar Rock reported a net loss of $107.2 million, including stock-based compensation of $17.9 million, for the quarter ended September 30, 2026, compared to a net loss of $102.2 million, including stock-based compensation of $18.3 million, for the quarter ended September 30, 2025. Net loss per common share was $0.81 for the quarter ended September 30, 2026, compared to $0.90 per common share for the quarter ended September 30, 2025.

The Company recorded net product revenue of $0.6 million from sales of ISEMBYLD in the U.S. for the quarter ended September 30, 2026. The Company did not record any revenue for the quarter ended September 30, 2025.

Cost of revenue was immaterial for the quarter ended September 30, 2026. Prior to the FDA approval of ISEMBYLD, product costs were expensed as research and development expense. The Company did not record any cost of revenue for the quarter ended September 30, 2025.

Research and development expense was $54.1 million, including $6.4 million in stock-based compensation, for the quarter ended September 30, 2026, compared to $50.5 million, including $5.5 million in stock-based compensation, for the quarter ended September 30, 2025.

Selling, general and administrative expense was $52.5 million, including $11.5 million in stock-based compensation, for the quarter ended September 30, 2026, compared to $53.1 million, including $12.8 million in stock-based compensation, for the quarter ended September 30, 2025.

As of September 30, 2026, Scholar Rock had cash, cash equivalents, and marketable securities of $413.6 million.

Scholar Rock will host a conference call and webcast today, Tuesday, November 10, at 8:00 a.m. ET to review its third quarter 2026 financial results and discuss recent business updates. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website athttp://investors.scholarrock.com.

To participate via telephone, please register in advancehere. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call.

A replay of the webcast will be available on the Company’s website for approximately 90 days.

Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Following FDA approval in September 2026, Scholar Rock is commercializing ISEMBLYD (apitegromab-mstn) in the U.S. for people living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. The Company plans to expand access to ISEMBYLD globally, in up to 50 countries worldwide, subject to regulatory approvals.

As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more about our neuromuscular franchise atScholarRock.comand follow @ScholarRock on X and on LinkedIn.

Scholar Rock®is a registered trademark and ISEMBYLD™is a trademark of Scholar Rock, Inc.

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X, or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding the U.S. commercial launch and commercial performance of ISEMBYLD, including patient and physician

demand, launch dynamics, patient enrollment trends, market acceptance, coverage and reimbursement, and the timing of an ISEMBYLD-specific J-code; expectations regarding its growth, strategy, progress and timing of its clinical trials and development programs for apitegromab, including its subcutaneous formulation, the potential characteristics and benefits of such formulation, and its engagement with regulators regarding the development path for such formulation, as well as the ongoing Phase 2 OPAL and FORGE trials, and for SRK-439, including the expected timing of topline data from its Phase 1 clinical trial and the timing of public disclosure of such data, the timing of any regulatory submissions, decisions and anticipated approvals, and the therapeutic potential, clinical benefits and safety of any product candidates; expectations regarding the timing and outcome of EMA review of the resubmitted MAA for apitegromab, including the expected timing of a CHMP opinion in the first half of 2027; expectations regarding the timing and outcome of PMDA review of the JNDA for apitegromab under priority review; expectations regarding the availability and timing of commercial supply of ISEMBYLD and apitegromab, including from Scholar Rock’s alternate fill-finish facility; expectations regarding the closing of the sale of Scholar Rock’s PRV, including the satisfaction of closing conditions, including the expiration of the applicable waiting period under the Hart-Scott- Rodino Antitrust Improvements Act, and the anticipated receipt and use of proceeds therefrom; plans to expand access to ISEMBYLD globally, including in up to 50 countries worldwide, and expectations regarding commercial launch timing in additional jurisdictions, and the achievement of important milestones, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical or clinical data; and the potential of its product candidates and proprietary platform. The use of words such as “may,” “might,” “could,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, whether nonclinical and clinical data, including the results from the Phase 3 SAPPHIRE trial and any results from ongoing or future clinical trials, including the Phase 2 OPAL clinical trial, the Phase 2 FORGE trial and the Phase 1 clinical trial of SRK-439, will be sufficient to support regulatory approval or further development; that nonclinical and clinical data, including the results from the Phase 2 or Phase 3 clinical trial of apitegromab, data from any ongoing or future trials of apitegromab or data for SRK-439, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates; whether the resubmitted MAA and the JNDA will be sufficient to support regulatory approval of apitegromab in the European Union and Japan, respectively, on the expected timelines or at all; Scholar Rock’s ability to successfully commercialize ISEMBYLD, including achieving market acceptance among patients, physicians and payors and obtaining adequate coverage and reimbursement; whether early patient and physician demand for ISEMBYLD translates into sustained patient treatment and product revenue; Scholar Rock’s ability to obtain regulatory approval for, and to successfully expand access to, ISEMBYLD in additional countries; Scholar Rock’s ability to maintain sufficient commercial supply of ISEMBYLD, including through its alternate fill-finish facility; whether the conditions to the closing of the PRV sale will be satisfied on the expected timeline or at all; Scholar Rock’s need for additional capital and its ability to obtain it on acceptable terms; Scholar Rock’s ability to manage expenses or provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline; information provided or decisions made by regulatory authorities, including regarding the development path for subcutaneous apitegromab; competition from third parties that are developing products for similar uses; Scholar Rock’s ability to obtain, maintain and protect its intellectual property; and Scholar Rock’s dependence on third parties for development and manufacture of apitegromab, ISEMBYLD and other product candidates including, without limitation, to supply commercial demand for ISEMBYLD and any clinical trials as well as those risks more fully discussed in the section entitled “Risk Factors” in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law. Scholar Rock Holding Corporation Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share data)

Scholar Rock Holding Corporation Condensed Consolidated Balance Sheets (unaudited) (in thousands)

Investors Laura Ekas, Ph.D. 917-439-0374 [email protected] Media Jeff Smith 682-401-8428 Molly MacLeod, Ph.D. 802-579-5995 [email protected]

Full text with the tables
                                                                    Exhibit 99.1
 Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business  
                                   Highlights                                   
U.S. launch of ISEMBYLD™ (apitegromab-mstn), the first and only muscle-targeted 
therapy for children and adults living with spinal muscular atrophy (SMA),      
underway following September 11, 2026 FDA approval                              
                                                                                
ISEMBYLD shipped to specialty network prior to quarter-end, reflecting Q3 2026  
ISEMBYLD revenue of $0.6 million                                                
                                                                                
Strong early patient and physician demand for ISEMBYLD, with initial patients   
infused in October 2026                                                         
                                                                                
Apitegromab Marketing Authorisation Application (MAA) for treatment of children 
and adults living with SMA resubmitted to European Medicines Agency (EMA) and   
validated in October 2026; on track for Committee for Medicinal Products for    
Human Use (CHMP) opinion in H1 2027                                             
                                                                                
Apitegromab Japanese New Drug Application (JNDA) for treatment of children and  
adults living with SMA submitted to Japan’s Pharmaceuticals and Medical Devices 
Agency (PMDA) and accepted under priority review                                
                                                                                
Cash, cash equivalents, and marketable securities of $413.6 million as of       
September 30, 2026                                                              
                                                                                
In November, reached definitive agreement to sell Priority Review Voucher (PRV) 
for $205 million; cash to be received upon closing                              
                                                                                
Management to host a conference call today at 8:00 a.m. ET                      
                                                                                
CAMBRIDGE, Mass.--(BUSINESS WIRE)— November 10, 2026 — Scholar Rock (NASDAQ:    
SRRK), a global biopharmaceutical company dedicated to improving the lives of   
patients with rare, severe, and debilitating neuromuscular diseases by applying 
its leading platform in myostatin biology, today reported financial results for 
the third quarter ended September 30, 2026, and provided an update on recent    
company developments.                                                           
                                                                                
“The third quarter was a defining period for Scholar Rock, marked by the FDA    
approval and U.S. launch of ISEMBYLD, the world’s first and only muscle-targeted
therapy for children and adults living with SMA,” said David L. Hallal, Chairman
and Chief Executive Officer of Scholar Rock. “We are very encouraged by the     
early ISEMBYLD launch dynamics in the U.S., where the breadth of early demand   
across SMA treatment centers, physicians, and patients reinforces the           
significant unmet need in the SMA community. With the U.S. launch underway, our 
regulatory applications advancing in Europe and Japan, important progress across
our world-leading anti-myostatin pipeline, and our strengthened financial       
position, we are building a foundation to redefine the treatment of             
neuromuscular disease globally and drive sustainable growth for years to come.” 
                                                                                
Business Highlights and Upcoming Milestones                                     
                                                                                
Apitegromab Spinal Muscular Atrophy (SMA) Program                               
                                                                                
ISEMBYLD (apitegromab-mstn) approved by FDA on September 11, 2026. ISEMBYLD is  
the first and only muscle-targeted therapy for SMA and is indicated for adults  
and children two years of age and older who are currently receiving a survival  
motor neuron 2 (SMN2)-targeted                                                  
                                                                                
treatment. In the Phase 3 pivotal, randomized, double-blind, placebo-controlled 
SAPPHIRE study, individuals receiving ISEMBYLD with an SMN2-targeted treatment  
demonstrated a robust, clinically meaningful improvement in motor function at   
one year while those on an SMN2-targeted therapy alone experienced a loss of    
motor function.                                                                 
                                                                                
U.S. launch of ISEMBYLD underway with strong early patient and physician demand 
. The U.S. team is in the field engaging with physicians, SMA care teams, and   
patients as well as national and regional payers. ISEMBYLD vials were labeled,  
packaged, and shipped to the specialty network within one week of FDA approval. 
A J-code application was submitted to the Centers for Medicare & Medicaid       
Services (CMS) in September for an ISEMBYLD-specific J-code on April 1, 2027.   
Encouraging early, broad-based demand for ISEMBYLD is reflected in the breadth  
of prescribing physicians and enrolling patients. Early launch dynamics are     
reinforcing the significant opportunity to serve children and adults with SMA in
the U.S.                                                                        
                                                                                
Apitegromab application in Europe on track for H1 2027 Committee for Medicinal  
Products for Human Use (CHMP) opinion . In alignment with guidance from the     
European Medicines Agency (EMA), Scholar Rock resubmitted the apitegromab       
Marketing Authorisation Application (MAA) for the treatment of children and     
adults living with SMA in October 2026. Following validation of the submission, 
review of the MAA is underway, and the Company expects a CHMP opinion in the    
first half of 2027. The resubmitted MAA includes Scholar Rock’s alternate fill- 
finish facility in place of the Catalent Indiana LLC fill-finish facility. The  
alternate fill-finish facility is the same site that supported the U.S. FDA     
approval of ISEMBYLD in September 2026. As the regulatory review progresses, the
Scholar Rock team in Europe continues to engage with key stakeholders on SMA    
disease awareness and education initiatives.                                    
                                                                                
Apitegromab Japanese New Drug Application (JNDA) submitted in Japan and accepted
under priority review. Scholar Rock submitted the apitegromab JNDA in Japan,    
which was accepted under priority review. For priority review applications,     
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has typically targeted
a review cycle of approximately nine months. In addition, apitegromab for the   
treatment of people living with SMA was granted an Orphan Drug Designation.     
                                                                                
Regulatory engagement for subcutaneous apitegromab program to progress. Scholar 
Rock has developed a high concentration subcutaneous formulation of apitegromab.
Following the September 11, 2026 FDA approval of ISEMBYLD, the Company is       
engaging with regulators on the development path for this formulation.          
Subcutaneous apitegromab is designed to provide optionality for the SMA         
community as a small volume, self- or caregiver-administered anti-myostatin     
antibody.                                                                       
                                                                                
Phase 2 OPAL trial advancing . Enrollment is well advanced and dosing is ongoing
(NCT07047144). The OPAL study is evaluating apitegromab in infants and toddlers 
with SMA under two years of age who have received an approved SMN1-targeted gene
therapy or who are receiving ongoing treatment with an approved SMN2-targeted   
therapy.                                                                        
                                                                                
Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program               
                                                                                
Enrollment and dosing in Phase 2 FORGE trial ongoing. The Phase 2 randomized,   
double-blind, placebo-controlled trial, called FORGE, is expected to enroll     
approximately 60 patients with FSHD who will be randomized 1:1 to receive either
apitegromab 10mg/kg IV or placebo every 4 weeks for 52 weeks. The primary       
endpoint is mean lean muscle volume (LMV) change from baseline at 12 months.    
Other endpoints include safety, pharmacokinetics/ pharmacodynamics,             
                                                                                
mean LMV change from baseline at 6 months, as well as several exploratory       
functional endpoints. In September 2026, the FDA granted Fast Track and Orphan  
Drug designations to apitegromab for the treatment of people living with FSHD.  
                                                                                
SRK-439 Program                                                                 
                                                                                
Phase 1 study in healthy volunteers ongoing. A Phase 1 study evaluating SRK-439 
in healthy volunteers is progressing well. Scholar Rock expects to have topline 
data by year end 2026 and plans to share data from this study in early 2027.    
SRK-439 is a novel, investigational, subcutaneously administered myostatin      
inhibitor that binds to pro- and latent myostatin with high affinity and        
selectivity. Based on non-clinical data, SRK-439 has the potential to potently  
inhibit myostatin and increase muscle mass.                                     
                                                                                
Financial Update                                                                
                                                                                
Definitive agreement to sell Rare Pediatric Disease Priority Review Voucher     
(PRV) for $205 million. In November, Scholar Rock entered into a definitive     
agreement to sell its PRV for $205 million. The closing of the PRV transaction  
is subject to customary closing conditions, including the expiration of the     
applicable waiting period under the Hart-Scott-Rodino (HSR) Antitrust           
Improvements Act. The cash will further strengthen the Company’s balance sheet  
with non-dilutive capital. The PRV was awarded following the September 2026 FDA 
approval of ISEMBYLD.                                                           
                                                                                
Third Quarter 2026 Financial Results                                            
                                                                                
Scholar Rock reported a net loss of $107.2 million, including stock-based       
compensation of $17.9 million, for the quarter ended September 30, 2026,        
compared to a net loss of $102.2 million, including stock-based compensation of 
$18.3 million, for the quarter ended September 30, 2025. Net loss per common    
share was $0.81 for the quarter ended September 30, 2026, compared to $0.90 per 
common share for the quarter ended September 30, 2025.                          
                                                                                
The Company recorded net product revenue of $0.6 million from sales of ISEMBYLD 
in the U.S. for the quarter ended September 30, 2026. The Company did not record
any revenue for the quarter ended September 30, 2025.                           
                                                                                
Cost of revenue was immaterial for the quarter ended September 30, 2026. Prior  
to the FDA approval of ISEMBYLD, product costs were expensed as research and    
development expense. The Company did not record any cost of revenue for the     
quarter ended September 30, 2025.                                               
                                                                                
Research and development expense was $54.1 million, including $6.4 million in   
stock-based compensation, for the quarter ended September 30, 2026, compared to 
$50.5 million, including $5.5 million in stock-based compensation, for the      
quarter ended September 30, 2025.                                               
                                                                                
Selling, general and administrative expense was $52.5 million, including $11.5  
million in stock-based compensation, for the quarter ended September 30, 2026,  
compared to $53.1 million, including $12.8 million in stock-based compensation, 
for the quarter ended September 30, 2025.                                       
                                                                                
As of September 30, 2026, Scholar Rock had cash, cash equivalents, and          
marketable securities of $413.6 million.                                        
                                                                                
Conference Call Information                                                     
                                                                                
Scholar Rock will host a conference call and webcast today, Tuesday, November   
10, at 8:00 a.m. ET to review its third quarter 2026 financial results and      
discuss recent business updates. To access the live audio webcast, please go to 
“Events and Presentations” in the Investors section of the Scholar Rock website 
athttp://investors.scholarrock.com.                                             
                                                                                
To participate via telephone, please register in advancehere. Upon registration,
all telephone participants will receive a confirmation email detailing how to   
join the conference call.                                                       
                                                                                
A replay of the webcast will be available on the Company’s website for          
approximately 90 days.                                                          
                                                                                
About Scholar Rock                                                              
                                                                                
Scholar Rock is delivering muscle-targeted breakthroughs to transform the       
treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases
where muscle atrophy remains a critical unmet need. Following FDA approval in   
September 2026, Scholar Rock is commercializing ISEMBLYD (apitegromab-mstn) in  
the U.S. for people living with SMA who are 2 years of age and older and        
currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. The    
Company plans to expand access to ISEMBYLD globally, in up to 50 countries      
worldwide, subject to regulatory approvals.                                     
                                                                                
As a global leader in myostatin biology, a field focused on proteins that       
regulate muscle mass, the biopharmaceutical company is named for the visual     
resemblance of a scholar rock to protein structures. Our commitment to unlock   
fundamentally different treatment approaches is powered by broad application of 
a proprietary platform, which has developed novel monoclonal antibodies to      
modulate protein growth factors with extraordinary selectivity. Scholar Rock    
works every day to create new possibilities for patients through its highly     
innovative anti-myostatin program, including opportunities in additional rare   
neuromuscular diseases. Learn more about our neuromuscular franchise            
atScholarRock.comand follow @ScholarRock on X and on LinkedIn.                  
                                                                                
Scholar Rock®is a registered trademark and ISEMBYLD™is a trademark of Scholar   
Rock, Inc.                                                                      
                                                                                
Availability of Other Information About Scholar Rock                            
                                                                                
Investors and others should note that we communicate with our investors and the 
public using our company website www.scholarrock.com, including, but not limited
to, company disclosures, investor presentations and FAQs, Securities and        
Exchange Commission filings, press releases, public conference call transcripts 
and webcast transcripts, as well as on X (formerly known as Twitter) and        
LinkedIn. The information that we post on our website, X, or LinkedIn could be  
deemed to be material information. As a result, we encourage investors, the     
media and others interested to review the information that we post there on a   
regular basis. The contents of our website or social media shall not be deemed  
incorporated by reference in any filing under the Securities Act of 1933, as    
amended.                                                                        
                                                                                
Forward-Looking Statements                                                      
                                                                                
This press release contains "forward-looking statements" within the meaning of  
the Private Securities Litigation Reform Act of 1995, including, but not limited
to, statements regarding Scholar Rock’s future expectations, plans and          
prospects, including without limitation, Scholar Rock’s expectations regarding  
the U.S. commercial launch and commercial performance of ISEMBYLD, including    
patient and physician                                                           
                                                                                
demand, launch dynamics, patient enrollment trends, market acceptance, coverage 
and reimbursement, and the timing of an ISEMBYLD-specific J-code; expectations  
regarding its growth, strategy, progress and timing of its clinical trials and  
development programs for apitegromab, including its subcutaneous formulation,   
the potential characteristics and benefits of such formulation, and its         
engagement with regulators regarding the development path for such formulation, 
as well as the ongoing Phase 2 OPAL and FORGE trials, and for SRK-439, including
the expected timing of topline data from its Phase 1 clinical trial and the     
timing of public disclosure of such data, the timing of any regulatory          
submissions, decisions and anticipated approvals, and the therapeutic potential,
clinical benefits and safety of any product candidates; expectations regarding  
the timing and outcome of EMA review of the resubmitted MAA for apitegromab,    
including the expected timing of a CHMP opinion in the first half of 2027;      
expectations regarding the timing and outcome of PMDA review of the JNDA for    
apitegromab under priority review; expectations regarding the availability and  
timing of commercial supply of ISEMBYLD and apitegromab, including from Scholar 
Rock’s alternate fill-finish facility; expectations regarding the closing of the
sale of Scholar Rock’s PRV, including the satisfaction of closing conditions,   
including the expiration of the applicable waiting period under the Hart-Scott- 
Rodino Antitrust Improvements Act, and the anticipated receipt and use of       
proceeds therefrom; plans to expand access to ISEMBYLD globally, including in up
to 50 countries worldwide, and expectations regarding commercial launch timing  
in additional jurisdictions, and the achievement of important milestones, the   
ability of any product candidate to perform in humans in a manner consistent    
with earlier nonclinical or clinical data; and the potential of its product     
candidates and proprietary platform. The use of words such as “may,” “might,”   
“could,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,”           
“estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other
similar expressions are intended to identify such forward-looking statements.   
All such forward-looking statements are based on management's current           
expectations of future events and are subject to a number of risks and          
uncertainties that could cause actual results to differ materially and adversely
from those set forth in or implied by such forward-looking statements. These    
risks and uncertainties include, without limitation, whether nonclinical and    
clinical data, including the results from the Phase 3 SAPPHIRE trial and any    
results from ongoing or future clinical trials, including the Phase 2 OPAL      
clinical trial, the Phase 2 FORGE trial and the Phase 1 clinical trial of       
SRK-439, will be sufficient to support regulatory approval or further           
development; that nonclinical and clinical data, including the results from the 
Phase 2 or Phase 3 clinical trial of apitegromab, data from any ongoing or      
future trials of apitegromab or data for SRK-439, are not predictive of, may be 
inconsistent with, or more favorable than, data generated from future or ongoing
clinical trials of the same product candidates; whether the resubmitted MAA and 
the JNDA will be sufficient to support regulatory approval of apitegromab in the
European Union and Japan, respectively, on the expected timelines or at all;    
Scholar Rock’s ability to successfully commercialize ISEMBYLD, including        
achieving market acceptance among patients, physicians and payors and obtaining 
adequate coverage and reimbursement; whether early patient and physician demand 
for ISEMBYLD translates into sustained patient treatment and product revenue;   
Scholar Rock’s ability to obtain regulatory approval for, and to successfully   
expand access to, ISEMBYLD in additional countries; Scholar Rock’s ability to   
maintain sufficient commercial supply of ISEMBYLD, including through its        
alternate fill-finish facility; whether the conditions to the closing of the PRV
sale will be satisfied on the expected timeline or at all; Scholar Rock’s need  
for additional capital and its ability to obtain it on acceptable terms; Scholar
Rock’s ability to manage expenses or provide the financial support, resources   
and expertise necessary to identify and develop product candidates on the       
expected timeline; information provided or decisions made by regulatory         
authorities, including regarding the development path for subcutaneous          
apitegromab; competition from third parties that are developing products for    
similar uses; Scholar Rock’s ability to obtain, maintain and protect its        
intellectual property; and Scholar Rock’s dependence on third parties for       
development and manufacture of apitegromab, ISEMBYLD and other product          
candidates including,                                                           
without limitation, to supply commercial demand for ISEMBYLD and any clinical
trials as well as those risks more fully discussed in the section entitled “Risk
Factors” in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2026, as well as discussions of potential risks, uncertainties,
and other important factors in Scholar Rock’s subsequent filings with the
Securities and Exchange Commission. Any forward-looking statements represent
Scholar Rock’s views only as of today and should not be relied upon as
representing its views as of any subsequent date. All information in this press
release is as of the date of the release, and Scholar Rock undertakes no duty to
update this information unless required by law. Scholar Rock Holding Corporation
Condensed Consolidated Statements of Operations (unaudited) (in thousands,
except share and per share data)
                                                                                
         Thr…                                     Nine                          
         Mon…                                     Mon…                          
         End…                                     End…                          
         Sep…                                     Sep…                          
         30,                                      30,                           
  Re…    2026               2025                  2026            2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Pr…                                                                           
  re…          $  570             $    —          $     570       $       —     
  net                                                                           
  Op…                                                                           
  ex…                                                                           
  Co…                                                                           
  of                8                  —                  8               -     
  re…                                                                           
  Re…                                                                           
  and             54…                50…                16…             16…     
  de…                                                                           
  Se…                                                                           
  ge…             52…                53…                15…             13…     
  and                                                                           
  ad…                                                                           
  To…                                                                           
  op…             10…                10…                31…             29…     
  ex…                                                                           
  Lo…                                                                           
  fr…             (1…  )             (1…  )             (3…  )          (2…  )  
  op…                                                                           
  Ot…                                                                           
  in…             (1…  )             1,…                (5…  )          5,…     
  (e…                                                                           
  net                                                                           
  Net    $        (1…  )    $        (1…  )    $        (3…  )    $     (2…  )  
  lo…                                                                           
  Net                                                                           
  lo…                                                                           
  per                                                                           
  sh…    $        (0…  )    $        (0…  )    $        (2…  )    $     (2…  )  
  ba…                                                                           
  and                                                                           
  di…                                                                           
  We…                                                                           
  av…                                                                           
  co…                                                                           
  sh…             13…                11…                13…             11…     
  ou…                                                                           
  ba…                                                                           
  and                                                                           
  di…                                                                           
                                                                                
Scholar Rock Holding Corporation Condensed Consolidated Balance Sheets
(unaudited) (in thousands)
                                                                                
                                    September 30, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Cash, cash equivalents and                                                    
  marketable                     $             413,599    $            367,563  
  securities                                                                    
  Other current assets                          19,830                  17,584  
  Total current assets                         433,429                 385,147  
  Other assets                                  12,543                  19,125  
  Total assets                   $             445,972    $            404,272  
  Liabilities and                                                               
  Stockholders' Equity                                                          
  Current liabilities            $              80,124    $             55,419  
  Long-term liabilities                        197,172                 103,365  
  Total liabilities                            277,296                 158,784  
  Total stockholders' equity                   168,676                 245,488  
  Total liabilities and                                                         
  stockholders'                  $             445,972    $            404,272  
  equity                                                                        
                                                                                
Investors Laura Ekas, Ph.D. 917-439-0374 [email protected] Media Jeff Smith
682-401-8428 Molly MacLeod, Ph.D. 802-579-5995 [email protected]

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SRRK/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.